01—Abstract
Summary
Summary of the 8-K filed April 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. filed this Form 8-K on April 30, 2026 to furnish its press release (Exhibit 99.1) announcing first quarter 2026 results and raised full-year 2026 guidance.
Revenue for the quarter was $3.54 billiona versus $3.35 billion a year earlier, up 5.8%, with organic growth of 3.1%, acquisitions contributing 1.4% and foreign exchange 1.3%. Diluted EPS rose to $3.35 from $2.52, and Adjusted EPS rose 10.6% to $4.25 from $3.84. Adjusted operating income was $507.9 million, a 14.4% margin versus 14.0% a year earlier.
Net earnings attributable to Labcorp Holdings Inc. were $277.8 millionb, compared with $212.8 million. Both segments grew. Diagnostics Laboratories revenue was $2.76 billion, up 5.0%, with an AOI margin of 16.6%.
Biopharma Laboratory Services revenue was $780.6 millionc, up 8.2%, with Central Labs revenue growth of 11.3% and Early Development growth of 0.6%. Biopharma's TTM book-to-bill was 1.04 and backlog was $8.64 billion. Operating cash flow was $191.5 million and free cash flow was $70.5 million, compared with negative $107.5 million a year earlier.
The company raised its 2026 guidance. Revenue is now expected at $14.65 billion to $14.80 billiond, growth of 5.0% to 6.1%, and Adjusted EPS at $17.70 to $18.35, up 13 cents at the midpoint to $18.03.
Free cash flow guidance was unchanged at $1.24 billion to $1.36 billion. Total debt rose to $6.33 billion at quarter end, which the company attributed to pre-funding of maturing debt, and cash was $981.1 million.
02—Key points
Key Highlights
- Q1 2026 revenue of $3.54 billion, up 5.8% year over year, with organic growth of 3.1%
- Diluted EPS of $3.35 versus $2.52 a year earlier; Adjusted EPS of $4.25, up 10.6%
- Adjusted operating income of $507.9 million, a 14.4% margin versus 14.0%
- Raised 2026 Adjusted EPS guidance to $17.70–$18.35 and revenue guidance to $14.65–$14.80 billion
- Biopharma Laboratory Services revenue up 8.2% to $780.6 million, with Central Labs growth of 11.3%
- Free cash flow of $70.5 million versus negative $107.5 million a year earlier; 2026 free cash flow guidance unchanged at $1.24–$1.36 billion
- Capital deployment in the quarter: $202.2 million in acquisitions, $98.0 million in share repurchases, $61.2 million in dividends; quarterly dividend of $0.72 per share declared
03—Questions
Frequently Asked Questions
How did Labcorp perform in the first quarter of 2026?
Revenue rose 5.8% to $3.54 billion, and diluted EPS increased to $3.35 from $2.52. Adjusted EPS rose 10.6% to $4.25. Adjusted operating margin expanded to 14.4% from 14.0%, driven mainly by organic growth.
What changed in the 2026 guidance?
Labcorp raised its full-year Adjusted EPS range to $17.70–$18.35 from $17.55–$18.25, up 13 cents at the midpoint. Enterprise revenue guidance rose to $14.65–$14.80 billion from $14.61–$14.79 billion, with growth now expected at 5.0% to 6.1%. Free cash flow guidance was unchanged at $1.24–$1.36 billion.
Which business segments drove results?
Diagnostics Laboratories revenue grew 5.0% to $2.76 billion, with organic growth of 2.9% and an AOI margin of 16.6%, despite adverse weather. Biopharma Laboratory Services revenue grew 8.2% to $780.6 million, led by Central Labs, while Early Development grew 0.6%.
How is Labcorp managing its balance sheet and capital returns?
Total debt was $6.33 billion and cash was $981.1 million at quarter end, with the company citing pre-funding of maturing debt. In the quarter it spent $202.2 million on acquisitions, repurchased $98.0 million of stock, and paid $61.2 million in dividends. It also declared a quarterly dividend of $0.72 per share payable June 11, 2026.
04—Continue